Resource Centers

View More HIV Liver Disease Sleep Disorders Biosimilars Covid-19 Asthma Multiple Sclerosis Post-Acute Care Prescription Digital Therapeutics Respiratory Conditions Type II Inflammation

HIV Liver Disease Sleep Disorders Biosimilars Covid-19 Asthma Multiple Sclerosis Post-Acute Care Prescription Digital Therapeutics Respiratory Conditions Type II Inflammation

Asembia’s 2022 Specialty Pharmacy Summit AMCP Annual The Improving Patient Access Podcast Wet Age-Related Macular Degeneration: Understanding Disease Impact and Refining Treatment Approaches AMCP Nexus Paradigms in Insulin Use for Type 2 Diabetes PBMI National Conference Respiratory Conditions Short on staff? Efficiency—not hiring—may be the best answer Supporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)

Asembia’s 2022 Specialty Pharmacy Summit AMCP Annual The Improving Patient Access Podcast Wet Age-Related Macular Degeneration: Understanding Disease Impact and Refining Treatment Approaches AMCP Nexus Paradigms in Insulin Use for Type 2 Diabetes PBMI National Conference Respiratory Conditions Short on staff? Efficiency—not hiring—may be the best answer Supporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)

View More Business Strategy Chronic Disease Consumers Drug Costs Drug Pipeline Formulary Health Management Health/Disease Strategy Hospitals & Providers Industry Analysis Pharmacy Politics and Policy Practice Management Reimbursement Technology

Business Strategy Chronic Disease Consumers Drug Costs Drug Pipeline Formulary Health Management Health/Disease Strategy Hospitals & Providers Industry Analysis Pharmacy Politics and Policy Practice Management Reimbursement Technology

Expert Interviews

Medical World News

Population Health Perspectives

Expert Interviews K-Cast Medical World News Podcasts Population Health Perspectives

MHE Publication

Supplements And Featured Publications

MHE Publication Supplements And Featured Publications

Sponsored Content

PBM Leaders Sponsored Sponsored Content Surveys

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Resource CentersSee All >

HIV
Liver Disease
Sleep Disorders
Biosimilars
Covid-19
Asthma
Multiple Sclerosis
Post-Acute Care
Prescription Digital Therapeutics
Respiratory Conditions
Type II Inflammation

Spotlight

Asembia’s 2022 Specialty Pharmacy Summit
AMCP Annual
The Improving Patient Access Podcast
Wet Age-Related Macular Degeneration: Understanding Disease Impact and Refining Treatment Approaches
AMCP Nexus
Paradigms in Insulin Use for Type 2 Diabetes
PBMI National Conference
Respiratory Conditions
Short on staff? Efficiency—not hiring—may be the best answer
Supporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)

BusinessSee All >

Business Strategy
Chronic Disease
Consumers
Drug Costs
Drug Pipeline
Formulary
Health Management
Health/Disease Strategy
Hospitals & Providers
Industry Analysis
Pharmacy
Politics and Policy
Practice Management
Reimbursement
Technology

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2022 MJH Life Sciences^™ and Managed Healthcare Executive. All rights reserved.

Most diabetes patients eventually need a second drug

July 1, 2004

Sulfonylureas or metformin are reasonable initial-medication choices to slow the progression of diabetes.